They are slaughtering BTG in the dose sales and consultant Comms...

First 34 Last

Share
Profile

Follow
JCoure

36,204 Posts.

931

18/01/18

09:03

Post #: 30390705
Share

Originally posted by cafa ↑

If the annual number comes in at the higher end, of around $85m, then the PE is 13.x.

I would have thought that this is a tad too low. As we have seen yesterday, any +ve news that could impact dose sales will bounce the SP upwards.

Confirmation of the RHS story from Ricky, and, or from RESIN would be a kicker in my book.

An NCCN recommendation to seperate treatment based on the source would be a bigger kicker, and I believe this is in progress. However they do not work in CAFA time scales

With both, I could see the SP going to the mid to high 20s as there would be a rerating of the the stock with the expected PE going back to the high teens, or even the 20s.

When the FDA give SRX the PMA extension for HCC, or better pan-liver, again we will see a rerating of the stock.

Can they make the $85m number? My view is that with a new senior management team they would be most foolish to put their balls on the line with a number they can't meet, assuming no black swan events.

Thus I conclude that the forward PE of less than 14, allows for some more upward movement in the SP. It will one most interesting to see which analyst comes out with the first report, or maybe we will have to wait until the results are published in 5 weeks time.

Expand

They are slaughtering BTG in the dose sales and consultant Comms space, marketing budget looks down as well, I wonder how they r doing it, looks pretty fabulous.

Market is obviously a little sceptical of management assertions, did the governance folk have a look behind the numbers? Have they hired any governance folk or is that a question the answer is beyond the capability of management?

SRX Price at posting: $17.83 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NHF

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

ACW

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial